Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jan 17;73(1):13. doi: 10.1007/s00262-023-03586-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — Anti-leukemia ability of nU-CAR-T19 cells in patients with R/R B-ALL. a MRD of bone marrow in patients with R/R B-ALL after infusion of nU-CAR-T19 cells. b The persistence and expansion of nU-CAR-T19 cells in vivo. c Compared to patients treated with U-CAR-T19 cells, a higher peak in CAR copy number was observed in patients infused with nU-CAR-T19 cells. d Dynamic changes in IL-6 levels in vivo after the infusion of nU-CAR-T19 cells. e Higher IL-6 levels were observed in patients treated with nU-CAR-T19 cells than in patients treated with U-CAR-T19 cells. f No NK cell activation after infusion of nU-CAR-T19 cells. The percentages of CD16⁺/CD56⁺ cells in patients treated with (n)U-CAR-T19 cells in vivo were analyzed using flow cytometry. After U-CAR-T19 cell infusion, the percentage of NK cells increased (n = 5). Statistical significance, two-tailed, non-paired or paired Student’s t tests were used, n.s, no significance, *P < 0.05, **P < 0.01